CALIWAY BIOPHARMACEUTICALS CO L
Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum's disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for … Read more
CALIWAY BIOPHARMACEUTICALS CO L (6919) - Total Liabilities
Latest total liabilities as of September 2025: NT$78.32 Million TWD
Based on the latest financial reports, CALIWAY BIOPHARMACEUTICALS CO L (6919) has total liabilities worth NT$78.32 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CALIWAY BIOPHARMACEUTICALS CO L - Total Liabilities Trend (2021–2024)
This chart illustrates how CALIWAY BIOPHARMACEUTICALS CO L's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
CALIWAY BIOPHARMACEUTICALS CO L Competitors by Total Liabilities
The table below lists competitors of CALIWAY BIOPHARMACEUTICALS CO L ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
A2 Milk Company Ltd
F:14L
|
Germany | €511.37 Million |
|
Life Time Group Holdings Inc
NYSE:LTH
|
USA | $4.84 Billion |
|
Isupetasys
KO:007660
|
Korea | ₩451.20 Billion |
|
Aneka Tambang (Persero) TBK (PT)
AU:ATM
|
Australia | AU$12.86 Trillion |
|
Technip Energies N.V
PINK:THNPF
|
USA | $7.13 Billion |
|
Thyssenkrupp AG O.N.
PINK:TYEKF
|
USA | $23.05 Billion |
|
Bharat Heavy Electricals Limited
NSE:BHEL
|
India | ₹475.72 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩836.23 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down CALIWAY BIOPHARMACEUTICALS CO L's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 114.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CALIWAY BIOPHARMACEUTICALS CO L's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CALIWAY BIOPHARMACEUTICALS CO L (2021–2024)
The table below shows the annual total liabilities of CALIWAY BIOPHARMACEUTICALS CO L from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$73.69 Million | -13.86% |
| 2023-12-31 | NT$85.55 Million | +24.31% |
| 2022-12-31 | NT$68.82 Million | +0.85% |
| 2021-12-31 | NT$68.24 Million | -- |